PubMed Health⌕ Search

PubMed · 7246432

Resolution and accuracy in two dimensional echocardiography.

Abstract

The resolution and accuracy of commercially available two dimensional echocardiographic systems were tested by imaging two types of in vitro test objects. One consisted of a series of fine parallel threads spaced at known intervals and the other was a tissue phantom in which a series of holes of known size had been cut. The echocardiographic systems tested included a mechanical single element sector scanner, a three element rotary sector scanner and a phased array system. Azimuthal resolution, lateral resolution and accuracy of horizontal distance measurements were assessed at depths of 2 and 6 cm. For each system, azimuthal resolution was better than lateral resolution, especially when assessed with use of the parallel threads. When the tissue phantom was imaged, the best resolution (2 mm in azimuthal and lateral directions) was obtained with the highest frequency transducer tested (3.5 MHz). The apparent size of a tissue defect was sensitive to gain settings, especially at a depth of 2 cm with lower frequency transducers; at a depth of 6 cm, echographic measurements of defect size were accurate to within 2.5 mm. Recent applications of two dimensional echocardiography require near the apparent limits of current equipment. It is recommended that the highest frequency transducer and lowest possible gain settings be used in these situations.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L A Latson, J P Cheatham, H P Gutgesell. 1981. Resolution and accuracy in two dimensional echocardiography.. https://doi.org/10.1016/0002-9149(81)90578-6

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Hypertrophic cardiomyopathy: a genome-wide association meta-analysis and polygenic risk score.

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a heritable trait with marked variability in expression and outcomes. Our aims were to discover new genetic loci associated with HCM and to test the effect of a new polygenic risk score (PRS) on incidence, phenotype and outcomes stratified by genotype status. METHODS: A discovery genome-wide association study (GWAS) was performed on 2284 HCM cases and 4525 controls. Two fixed-effects meta-analyses combined our discovery GWAS with single-trait and multi-trait results from a published study. Discovered loci underwent comprehensive bioinformatic analysis including functional and druggability annotations. A PRS using loci from the two meta-analyses was evaluated for association with HCM diagnosis in 411 213 individuals from UK Biobank (UKBB); imaging phenotypes in individuals without HCM; a composite endpoint (including all-cause mortality and transplantation); and sudden cardiac death (SCD) in 1756 HCM cases. PRS analyses were stratified by genotype status. RESULTS: Three loci were found in the discovery GWAS (BAG3, FHOD3 and novel locus PPP1R3A). In the meta-analyses, 70 unique loci were identified, four novel (MYPN, YWHAE, NOS1AP and OBSCN). Bioinformatic analyses identified NOS1AP as a candidate HCM gene. A new PRS was significantly associated with HCM diagnosis (HR=3.19, 95% CI 2.46 to 4.14 for top 5% vs lower 95%; HR=1.88, 95% CI 1.72 to 2.06 per SD increase). Significant associations were found between PRS and greater left ventricular (LV) wall thickness and higher LV ejection fraction in UKBB participants without HCM. Genotype-negative HCM cases in the top 20% of the PRS distribution had an increased risk of SCD (HR=2.72, 95% CI 1.03 to 7.17). CONCLUSIONS: We report novel HCM loci. A new PRS predicted the risk of HCM development and associated imaging characteristics in the UKBB and outcomes in an HCM cohort.

Cardiomyopathies↗

Integrative omics analysis identifies biomarkers of septic cardiomyopathy.

Septic Cardiomyopathy (SCM) is a syndrome of acute cardiac dysfunction in septic patients, unrelated to cardiac ischemia. Multiomics studies including transcriptomics and proteomics have provided new insights into the mechanisms of SCM. In here, a rat model of SCM was established by intraperitoneal injection of lipopolysaccharide (LPS). Biomarkers of SCM were characterized via a multi-omics analysis. The differentially expressed (DE) mRNAs predominantly appeared in pathways linked to the immune response, inflammatory response, and the complement and coagulation cascades, while DE proteins were mainly enriched in pathways associated with the complement and coagulation cascades. On this basis, the integrated analysis was performed between transcriptome and proteome. The potential biomarkers were further verified by RT-qPCR and WB. The current proteotranscriptomic research has furnished a valuable dataset and fresh perspectives that will enhance our comprehension of the development of SCM. This, in turn, is expected to expedite the formulation of novel approaches for the prevention and management of SCM in patients.

Cardiomyopathies↗